Dermatological Complications of Systemic Therapies for Melanoma

2020 ◽  
pp. 1337-1358
Author(s):  
Egle Ramelyte ◽  
Reinhard Dummer ◽  
Cristina Libenciuc ◽  
Gregory S. Phillips ◽  
Mario E. Lacouture ◽  
...  
Keyword(s):  
Systemic Therapies

Impact of novel systemic therapies on the first‐year costs of care for melanoma among Medicare beneficiaries

Cancer ◽  
2021 ◽  
Author(s):  
Kemal Caglar Gogebakan ◽  
Kumar Mukherjee ◽  
Elizabeth G. Berry ◽  
Kemal Sonmez ◽  
Sancy A. Leachman ◽  
...  
Keyword(s):  
First Year ◽  
Medicare Beneficiaries ◽  
Costs Of Care ◽  
Systemic Therapies

scholarly journals 1627MO Systemic therapies in advanced epithelioid haemangioendothelioma (EHE): A retrospective international series from the World Sarcoma Network

2020 ◽  
Vol 31 ◽  
pp. S977
Author(s):  
A.M. Frezza ◽  
V. Ravi ◽  
S. Lo Vullo ◽  
F. Tolomeo ◽  
T. Wei-Wu Chen ◽  
...  
Keyword(s):  
The World ◽  
Epithelioid Haemangioendothelioma ◽  
Systemic Therapies

scholarly journals Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1377
Author(s):  
Konstantinos Venetis ◽  
Roberto Piciotti ◽  
Elham Sajjadi ◽  
Marco Invernizzi ◽  
Stefania Morganti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Clinical Management ◽  
Bone Destruction ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Incurable Condition ◽  
Skeletal Related Events ◽  
Relevant Topic ◽  
Systemic Therapies

Despite the remarkable advances in the diagnosis and treatment of breast cancer patients, the presence or development of metastasis remains an incurable condition. Bone is one of the most frequent sites of distant dissemination and negatively impacts on patient’s survival and overall frailty. The interplay between tumor cells and the bone microenvironment induces bone destruction and tumor progression. To date, the clinical management of bone metastatic breast cancer encompasses anti-tumor systemic therapies along with bone-targeting agents, aimed at slowing bone resorption to reduce the risk of skeletal-related events. However, their effect on patients’ survival remains controversial. Unraveling the biology that governs the interplay between breast neoplastic cells and bone tissue would provide means for the development of new therapeutic agents. This article outlines the state-of-the art in the characterization and targeting the bone metastasis in breast cancer, focusing on the major clinical and translational studies on this clinically relevant topic.

scholarly journals Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2708
Author(s):  
Alice Boilève ◽  
Marc Hilmi ◽  
Matthieu Delaye ◽  
Annemilaï Tijeras-Raballand ◽  
Cindy Neuzillet
Keyword(s):  
Clinical Practice ◽  
Single Agent ◽  
Survival Rates ◽  
Critical Evaluation ◽  
Treatment Modalities ◽  
Molecular Profile ◽  
Clinical Activity ◽  
Liver Malignancies ◽  
Antiangiogenic Drugs ◽  
Systemic Therapies

Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) exhibit a poor prognosis with 5-year overall survival rates around 15%, all stages combined. Most of these primary liver malignancies are metastatic at diagnostic, with only limited therapeutic options, relying mainly on systemic therapies. Treatment modalities are different yet partially overlapping between HCC and BTC. The complex molecular profile of BTC yields to several actionable therapeutic targets, contrary to HCC that remains the field of antiangiogenic drugs in non-molecularly selected patients. Immunotherapy is now validated in the first line in HCC in combination with bevacizumab, while clinical activity of single agent immunotherapy appears limited to a subset of patients in BTC, still poorly characterized, and combinations are currently under investigation. In this review, we provide a critical evaluation and grading of clinical relevance on (i) the main prognostic biomarkers in HCC and BTC, (ii) the main theragnostic biomarkers in both tumors, and lastly (iii) what is recommended in clinical practice.

Metastases of Urothelium Carcinoma: Differential Diagnosis, Resection, and Survival

2021 ◽  
Author(s):  
Selma Oguzhan ◽  
Stefan Sponholz ◽  
Moritz Schirren ◽  
Mesut Mese ◽  
Joachim Schirren
Keyword(s):  
Differential Diagnosis ◽  
Multimodal Therapy ◽  
Pulmonary Metastases ◽  
Univariate Analysis ◽  
Pulmonary Carcinoma ◽  
Therapy Regimen ◽  
Urothelial Carcinomas ◽  
Common Diagnosis ◽  
Histological Confirmation ◽  
Systemic Therapies

Abstract Background Due to its very aggressive nature and low survival chances, the metastasized urothelium carcinoma poses a challenge in regard to therapy. The gold-standard chemotherapy is platinum based. The therapy options are considered controversial, including new systemic therapies. In this respect, surgical therapies, as already established for pulmonary metastases of other tumor entities play an increasingly important role. The consumption of nicotine is a risk factor not only for urothelium carcinoma but also for a pulmonary carcinoma. Thus, we examined the frequency of a second carcinoma in this cohort. Methods We retrospectively examined patients who had a differential diagnosis of pulmonary metastases, as well as those patients who underwent a surgery due to pulmonary metastases of a urothelium carcinoma between 1999 and 2015. Results A total of 139 patients came to our clinic with the differential diagnosis of pulmonary metastases of a urothelium carcinoma. The most common diagnosis was pulmonary carcinoma (53%). Thirty-one patients underwent surgeries due to pulmonary metastases of a urothelium carcinoma. The median survival was 53 months and the 5-year survival was 51%. With the univariate analysis, only the relapse-free interval of more than 10 months was statistically significant (p < 0.001). Conclusion There is a high coincidence of urothelial carcinoma and lung carcinoma. A histological confirmation should be endeavored. Selected patients undergoing a pulmonary metastasis resection have a survival advantage during the multimodal treatment of pulmonary metastasized urothelial carcinomas. For a definitive recommendation, randomized trials including a uniform multimodal therapy regimen and higher numbers of patients are necessary.

scholarly journals Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities

2021 ◽  
Vol 22 (6) ◽  
pp. 3117
Author(s):  
Loredana Lorusso ◽  
Virginia Cappagli ◽  
Laura Valerio ◽  
Carlotta Giani ◽  
David Viola ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Kinase Inhibitors ◽  
Therapeutic Option ◽  
Progression Free Survival ◽  
Thyroid Cancers ◽  
Poorly Differentiated ◽  
Differentiated Thyroid Cancers ◽  
Approved Drugs ◽  
New Generation ◽  
Systemic Therapies

Differentiated thyroid cancers (DTC) are commonly and successfully treated with total thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only treated with surgery but only intrathyroidal tumors are cured. The worst prognosis is for anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC). Whenever a local or metastatic advanced disease is present, other treatments are required, varying from local to systemic therapies. In the last decade, the efficacy of the targeted therapies and, in particular, tyrosine kinase inhibitors (TKIs) has been demonstrated. They can prolong the disease progression-free survival and represent the most important therapeutic option for the treatment of advanced and progressive thyroid cancer. Currently, lenvatinib and sorafenib are the approved drugs for the treatment of RAI-refractory DTC and PDTC while advanced MTC can be treated with either cabozantinib or vandetanib. Dabrafenib plus trametinib is the only approved treatment by FDA for BRAFV600E mutated ATC. A new generation of TKIs, specifically for single altered oncogenes, is under evaluation in phase 2 and 3 clinical trials. The aim of this review was to provide an overview of the current and future treatments of thyroid cancer with regards to the advanced and progressive cases that require systemic therapies that are becoming more and more targeted on the molecular identity of the tumor.

Sign in / Sign up

Export Citation Format

Share Document